Herceptin, Trastuzumab

Bookmark

Add to MyYahoo RSS

Herceptin, Trastuzumab News

News on Herceptin, Trastuzumab (generic) continually updated from thousands of sources around the net.

4 hrs ago | Bloomberg

Stolen Vials of Cancer Drug Reintroduced as Counterfeits

Vials of the cancer drug Herceptin probably stolen in Italy have been tampered with and reintroduced into the medicine supply chain, the European Medicines Agency said.

Comment?

Related Topix: Medicine, Europe, Finland, World News

8 hrs ago | Pharmaceutical Processing

EMA Reports Vials of Falsified Herceptin Identified

The European Medicines Agency has been informed that vials of the cancer medicine Herceptin , thought to have been stolen in Italy, including from hospitals, have been tampered with and re-introduced under false credentials into the supply chain in some countries.

Comment?

Related Topix: Medicine

9 hrs ago | Reuters

BRIEF-EU medicines agency warns of stolen Roche cancer drug

* European Medicines Agency - although only a small number of vials is thought to be affected, the marketing authorisation holder for Herceptin, as a precautionary measure, is recalling vials suspected of having being falsified

Comment?

Related Topix: Medicine

Mon Apr 14, 2014

IPKat

Another two bite the dust - Hospira v Genentech

The IPKat has just been perusing the meaty yet compact decision in the case of Hospira v Genentech ) which came out last Thursday from Mr Justice Birss.

Comment?

Related Topix: Genentech, Startups, Health, Breast Cancer, Healthcare Law, Law

Thu Apr 10, 2014

Reuters

UPDATE 1-Hospira wins UK case to overturn patents on Roche drug Herceptin

Hospira has successfully overturned two patents on Roche's blockbuster breast cancer drug Herceptin in Britain, clearing the way for it to launch a cheaper copycat version in the country.

Comment?

Related Topix: Medicine, Cancer, Health, Breast Cancer

Hispanic Business

Findings from Singapore National University in the Area of Cancer Therapy Described

Editor at Biotech Week -- Investigators publish new report on Oncology. According to news reporting from Singapore, Singapore, by NewsRx journalists, research stated, "Drug formulation by ligand conjugated nanoparticles of biodegradable polymers has become one of the most important strategies in drug targeting.

Comment?

Related Topix: National University, Journalism, Medicine

Medical News Today

Indication of major added benefit for trastuzumab emtansine in...

The antibody-drug conjugate trastuzumab emtansine has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast cancer that is HER2-positive, i.e. that overexpresses the human epidermal growth factor receptor 2. Patients must have already received trastuzumab or a taxane - alone or in ... (more)

Comment?

Related Topix: Medicine, Health, Breast Cancer, Xeloda, Capecitabine (generic)

Wed Apr 09, 2014

Hispanic Business

Puma Biotechnology Presents Positive PB272 Phase II Data from I-SPY 2 TRIAL

The I-SPY 2 TRIAL is a randomized Phase II clinical trial for women with newly diagnosed Stage 2 or higher breast cancer that addresses whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy.

Comment?

Related Topix: Medicine, Breast Cancer, Health, Doxorubicin (generic), Adriamycin, Doxil

Tue Apr 08, 2014

BioSpace

Kadmon Corporation Presents Preclinical Results Demonstrating KD019...

Kadmon Corporation, LLC, today announced the presentation of preclinical data demonstrating the activity, in trastuzumab resistant HER2+ breast cancer, of KD019, the Company's orally bioavailable spectrum selective small molecule kinase inhibitor of Src, HER2, EGFR and VEGFR2/KDR.

Comment?

Related Topix: Health, Breast Cancer

Mon Apr 07, 2014

Hispanic Business

Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL

The presentation entitled 'Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL' was presented today at the session entitled 'Clinical Trials Symposium: Biomarker Driven Clinical Trials.'

Comment?

Related Topix: Medicine, Breast Cancer, Health, Doxorubicin (generic), Adriamycin, Doxil, Cyclophosphamide (generic), Cytoxan

EurekAlert!

Trastuzumab emtansine: indication of major added benefit in 1 subpopulation

The antibody-drug conjugate trastuzumab emtansine has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast cancer that is HER2-positive, i.e. that overexpresses the human epidermal growth factor receptor 2. Patients must have already received trastuzumab or a taxane - alone or in ... (more)

Comment?

Related Topix: Medicine, Health, Breast Cancer, Xeloda, Capecitabine (generic)

Sun Apr 06, 2014

GlobeNewswire

Basilea's oncology drug candidate BAL101553 demonstrates broad...

Basilea Pharmaceutica Ltd. reported today that new data demonstrating the broad activity of Basilea's novel oncology drug candidate BAL101553 in pre-clinical models of human breast cancer, including models resistant to standard agents used for the treatment of breast cancer, were presented at the American Association of Cancer Research Annual ... (more)

Comment?

Related Topix: Oncology, Medicine, Cancer, Health, Breast Cancer, Stanford University

Fri Apr 04, 2014

BioMed Central

Complete pathologic response of HER2-positive breast cancer liver...

Although breast cancer frequently metastasizes to the bones and brain, rarely breast cancer patients may develop isolated liver metastasis.

Comment?

Related Topix: Medicine, Health, Breast Cancer

Thu Apr 03, 2014

Hispanic Business

biOasis Presents Results From It's BT2111 Program at International Cancer Research Conference

Transcend, a protein vector for brain delivery, allows trastuzumab to reach the brain at effective concentration after incorporation to form BT2111 Session: Immune Mechanisms Invoked by Radiation, Chemotherapy, or Targeted Therapy Presentation 2653.

Comment?

Related Topix: Cancer, Medicine, Health, Breast Cancer

Wed Apr 02, 2014

Hispanic Business

Study Data from Razi Vaccine and Serum Research Institute Update Knowledge of Breast Cancer

Intensification of antiproliferative activity of trastuzumab through construction of immunotoxins and nano-immunoconjugates is a promising approach for treatment of cancer."

Comment?

Related Topix: Medicine

Hispanic Business

Researchers Submit Patent Application, 'Method and Apparatus for...

News editors obtained the following quote from the background information supplied by the inventors: "The present invention relates to a method and a kit for predicting a cytotoxic activity, in particular, an antibody-dependent cellular cytotoxic activity.

Comment?

Related Topix: Inventions, Science / Technology, Medicine

BioSpace

Synthon Pharmaceuticals??'s Anti-HER2 ADC Frontrunner SYD985...

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 .

Comment?

Related Topix: Medicine

Wed Mar 26, 2014

P&T Community

Report: Breast Cancer Treatment Will Become More Dynamic as Companies ...

Decision Resources Group, a health care research firm located in Burlington, Mass., finds that efficacy more than any other factors drives oncologists' prescribing of targeted therapies for breast cancer.

Comment?

Related Topix: Medicine, Health, Breast Cancer, Cancer, Burlington, MA, Oncology

Mon Mar 24, 2014

Sys-Con Media

Investigation Report on China Trastuzumab Market, 2009-2018

Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor.

Comment?

Related Topix: Medicine, Health, Breast Cancer

Mon Mar 17, 2014

Hispanic Business

Galena Biopharma Reports Fourth Quarter and Year End 2013 Results

"The last year has been transformational for Galena as we progressed from a development stage company to a revenue-generating commercial organization with products and programs that span the entire cancer care spectrum, including five ongoing or planned mid-to-late stage clinical trials," said and Chief Executive Officer.

Comment?

Related Topix: Biotech, RXi Pharmaceuticals, Medicine, Marketing

•••
•••
•••
•••
•••
•••
•••
•••